. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: J Allergy Clin Immunol. 2017 Dec 19;141(4):1459–1467.e2. doi: 10.1016/j.jaci.2017.09.043

Table 3.

Asthma severity during daily or step-up inhaled corticosteroid (ICS) intervention by BMI-status

	BMI-percentile
Daily ICS^*	10–84^th (N=328)	≥85^th (N=157)	p-value
Asthma Symptom Days, mean (95% CI)¹	47.2 (40.8, 54.7)	43.0 (35.1, 52.6)	0.44³
Prednisone bursts, mean (95% CI)²	0.6 (0.5, 0.8)	0.8 (0.6, 1.1)	0.10³

Intermittent short-term ICS^**
N	71	33
Total intervention days, median (IQR)	359 (350, 367)	362 (343, 369)
Asthma Symptom Days, mean (95% CI)¹	61.8 (48.1, 79.3)	52.9 (36.9, 76.0)	0.46⁴
Prednisone bursts, mean (95% CI)²	1.1 (0.8, 1.6)	0.8 (0.5, 1.3)	0.25⁴

Intermittent as needed ICS^***
N	140	75
Total intervention days, median (IQR)	113 (111, 117)	113 (112, 118)
Asthma Symptom Days, mean (95% CI)¹	53.3 (42.1, 67.4)	47.3 (35.0, 63.9)	0.53⁴
Prednisone bursts, mean (95% CI)²	1.0 (0.7, 1.4)	1.1 (0.7, 1.7)	0.72⁴

BMI – body mass index, SFD – symptom free days.

^{* -}

data combined from INFANT, PEAK and MIST trials,

^{** -}

data from MIST trial,

^{*** -}

data from INFANT trial.

^{1 –}

annualized symptom days.

^{2 –}

bursts represent new oral steroid starts.

^{3 –}

p-values adjusted for trial and race/ethnicity

^{4 –}

p-values adjusted for race/ethnicity